T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant
Neurosurgical Review · 2024
DOI: 10.1007/s10143-024-02632-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurosurgical Review, 2024. Verfasst von Shumpei Onishi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-855…. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, Isocitrate Dehydrogenase, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.
Abstract (Originalsprache)
Introduction
The WHO classification of central nervous system tumors (5th edition) classified astrocytoma, IDH-mutant accompanied with CDKN2A/B homozygous deletion as WHO grade 4. Loss of immunohistochemical (IHC) staining for methylthioadenosine phosphorylase (MTAP) was developed as a surrogate marker for CDKN2A-HD. Identification of imaging biomarkers for CDKN2A status is of immense clinical relevance. In this study, we explored the association between radiological characteristics of non-enhancing astrocytoma, IDH-mutant to the CDKN2A/B status.
Methods
Thirty-one cases of astrocytoma, IDH-mutant with MTAP results by IHC were included in this study. The status of CDKN2A was diagnosed by IHC staining for MTAP in all cases, which was further confirmed by comprehensive genomic analysis in 12 cases. The T2-FLAIR mismatch sign, cystic component, calcification, and intratumoral microbleeding were evaluated. The relationship between the radiological features and molecular pathological diagnosis was analyzed.
Results
Twenty-six cases were identified as CDKN2A-intact while 5 cases were CDKN2A-HD. The presence of > 33% and > 50% T2-FLAIR mismatch was observed in 23 cases (74.2%) and 14 cases (45.2%), respectively, and was associated with CDKN2A-intact astrocytoma ( p = 0.0001, 0.0482). None of the astrocytoma, IDH-mutant with CDKN2A-HD showed T2-FLAIR mismatch sign. Cystic component, calcification, and intratumoral microbleeding were not associated with CDKN2A status.
Conclusion
In patients with non-enhancing astrocytoma, IDH-mutant, the T2-FLAIR mismatch sign is a potential imaging biomarker for the CDKN2A-intact subtype. This imaging biomarker may enable preoperative prediction of CDKN2A status among astrocytoma, IDH-mutant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-8551, Hiroshima, Japan.
- Department of Pediatric Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
- Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-8551, Hiroshima, Japan. fyama@hiroshima-u.ac.jp.
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Medical Division Technical Center, Hiroshima University, Hiroshima, Japan.
Förderung
- Hiroshima University
Zitieren
APA
Onishi, S., Kojima, M., Yamasaki, F., Amatya, V. J., Yonezawa, U., Taguchi, A., Ozono, I., Go, Y., Takeshima, Y., Hiyama, E., & Horie, N. (2024). T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant. Neurosurgical Review. https://doi.org/10.1007/s10143-024-02632-5
Vancouver
Onishi S, Kojima M, Yamasaki F, Amatya VJ, Yonezawa U, Taguchi A, et al. T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant. Neurosurgical Review. 2024. doi:10.1007/s10143-024-02632-5
BibTeX
@article{Onishi2024,
author = {Onishi, Shumpei and Kojima, Masato and Yamasaki, Fumiyuki and Amatya, Vishwa Jeet and Yonezawa, Ushio and Taguchi, Akira and Ozono, Iori and Go, Yukari and Takeshima, Yukio and Hiyama, Eiso and Horie, Nobutaka},
title = {T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant},
journal = {Neurosurgical Review},
year = {2024},
doi = {10.1007/s10143-024-02632-5}
}
EUVIMED